AI that moves at biotech speed — from discovery to commercialization
Discovery and commercialization are gated by documents, data, and timelines — and you don't need a company-wide AI mandate to start moving. We build AI that compresses those cycles inside your validated, governed environment: matching patients to trials, accelerating regulatory work, and giving lean biotech and enterprise pharma teams alike a live view of portfolio risk and return. Start with one high-value workflow, prove it, then scale.
Why AI mattersin Life Sciences.
In life sciences, breakthroughs are gated by documents, data, and time. AI matters when it compresses those cycles without compromising scientific or regulatory rigor.
Our point of view is value first, measured in dollars and timelines. The teams that win with AI are the ones that can move — so we prove ROI in a single workflow, no company-wide mandate required, then scale. We amplify your scientists and reviewers rather than replace them, and build inside your validated, governed environment.
- 01Time is the costEvery month of delay is value lost.
- 02Documents gate everythingTrials and submissions drown in paperwork AI can read.
- 03Rigor can't slipSpeed only counts inside a validated process.
- 04Data is the assetDecades of research, finally searchable.
How we workin Life Sciences.
One method, tuned to your context: we design the whole system — people and AI — rank every move by ROI across four lenses, and build in iterative cycles that compound value.
Design the whole system
We map discovery-to-commercialization workflows end-to-end, designing where AI drafts and where qualified reviewers approve — with the change management to bring scientists and regulatory teams along.
Quantify the value
We score each opportunity across four lenses — timeline, cost, scientific and regulatory rigor, and risk — prioritizing the document- and data-heavy cycles where AI compresses months into weeks.
Tailor to your context
We build inside your validated, governed environment, integrating with your CTMS, regulatory, and data platforms rather than replacing them — with full traceability for audit and inspection.
Iterate and compound
We deploy a focused workflow, measure against your timelines and quality gates, and iterate each cycle — compounding speed without compromising rigor.
The AI opportunityin Life Sciences.
faster regulatory filing timelines at leading pharma
highest-value AI use cases mapped per function
target ROI within 90 days
- 1McKinsey, 2025 — filings delivered 8–12 weeks after database lock
- 2AWSM LABS CRFT engagement guarantee — 3x ROI on the build fee by day 90, or we keep working at no charge
Photo: Pexels
Purpose-built applicationsfor Life Sciences.
Intelligent Clinical Trial Matching
An AI agent scans patient records, trial eligibility criteria, and site capacity in real time — automatically surfacing the best candidates and reducing enrollment timelines by months.
CRFT builds the matching engine, integrations, and investigator portal.
Regulatory Submission Accelerator
Compress months of regulatory document preparation into weeks — AI drafts, cross-references, and validates submissions against FDA and EMA requirements automatically.
CRFT engineers the document intelligence pipeline from ingestion to submission-ready output.
R&D Portfolio Intelligence
A live dashboard tracks the ROI trajectory of every compound in your pipeline — flagging risk signals, budget overruns, and competitive shifts before quarterly reviews.
KNTRL provides real-time portfolio visibility and optimization signals.
AI Opportunity Mapping — Biotech & Pharma
A structured assessment finds the highest-value AI use cases for your team — whether you're a lean preclinical biotech or an enterprise pharma — each with projected returns, so you start with proof, not a company-wide program.
SPRK delivers the diagnostic and ROI-backed activation roadmap.
Custodial ROI: The Fourth Lens — and the Only One Someone Else Grades
You grade three of your four AI ROI lenses. Somebody else grades the fourth, and you will not meet them until diligence. In 2014, 87 percent of dealmakers said much the same about cyber security — folded into a general IT review, not a risk category in its own right. Three years later Verizon cut $350 million off the price of Yahoo.
Pablo Cruz Pou · September 14, 2026 · 22 min read
The Four-Lens AI ROI System
In July 2025, the most-quoted number in enterprise AI said 95 percent of deployments returned nothing. Eight months later, a survey of middle-market leaders said 97 percent of AI pilots had succeeded. Neither measured a P&L. Both were describing your portfolio.
Pablo Cruz Pou · September 14, 2026 · 19 min read
Experiential ROI
Your adoption dashboard says the rollout worked. Usage is up, logins are daily, every rep on the team shows green. Ask five of those reps how they actually feel about the tool, and you'll hear something the dashboard was never built to show you.
Pablo Cruz Pou · September 4, 2026 · 16 min readLife Sciences,answered.
We design for your validated environment from day one — defining where AI drafts and where qualified reviewers approve, with full traceability for audit and inspection readiness.